Testing insulin‐like growth factor messenger RNA–binding protein 3 as a surrogate immunohistochemical marker for indeterminate thyroid nodules with THADA fusion in both cytologic and surgical specimens
Cancer Cytopathology · 2026
DOI: 10.1002/cncy.70076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cytopathology, 2026. Verfasst von Di Ai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Thyroid Nodule, Biomarkers, Tumor, Thyroid Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Background
Thyroid adenoma‐associated ( THADA ) gene fusions are recurrent alterations in thyroid nodules that lead to the overexpression of insulin‐like growth factor messenger RNA–binding protein 3 (IMP3). Although IMP3 immunohistochemistry has been studied in thyroid tumors, its utility for detecting THADA fusion–positive thyroid specimens remain unassessed.
Methods
The authors evaluated IMP3 expression in cytologic and surgical specimens from 20 indeterminate thyroid nodules. Eleven cases harbored THADA fusions, including THADA::IGF2BP3 ( n = 9) and THADA::TRA2A ( n = 2), whereas nine control cases lacked detectable THADA fusions. Hematoxylin‐and‐eosin staining and immunohistochemistry for IMP3 and NRAS Q61R were performed on available cell blocks and surgical specimens. Staining was scored based on extent and intensity, with a composite score >2 considered positive.
Results
All nodules with THADA fusions exhibited strong, diffuse, cytoplasmic IMP3 staining in lesional follicular cells, with no staining in adjacent normal thyroid tissue. All control cases were negative for IMP3. NRAS Q61R immunostaining was negative across all cases.
Conclusions
The current findings in a limited cohort demonstrate that IMP3 is a promising surrogate marker for indeterminate thyroid nodules with THADA fusions in both cytologic and surgical specimens. In addition, IMP3 staining may aid in detecting subtle capsular or vascular invasion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
- Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
- School of Medicine, University of Massachusetts, Boston, Massachusetts, USA.
- Department of Pathology and Laboratory Medicine, School of Medicine, Oregon Health Science University, Portland, Oregon, USA.
ORCID-Profile: Di Ai, Wen-Yu Hsiao, Qiuying Shi
Zitieren
APA
Ai, D., Zhang, Y., Viswanathan, K., Zhang, J., Magliocca, K. R., Steward-Tharp, S., Hsiao, W. Y., & Shi, Q. (2026). Testing insulin‐like growth factor messenger RNA–binding protein 3 as a surrogate immunohistochemical marker for indeterminate thyroid nodules with THADA fusion in both cytologic and surgical specimens. Cancer Cytopathology. https://doi.org/10.1002/cncy.70076
Vancouver
Ai D, Zhang Y, Viswanathan K, Zhang J, Magliocca KR, Steward-Tharp S, et al. Testing insulin‐like growth factor messenger RNA–binding protein 3 as a surrogate immunohistochemical marker for indeterminate thyroid nodules with THADA fusion in both cytologic and surgical specimens. Cancer Cytopathology. 2026. doi:10.1002/cncy.70076
BibTeX
@article{Ai2026,
author = {Ai, Di and Zhang, Youjie and Viswanathan, Kartik and Zhang, Jilun and Magliocca, Kelly R and Steward-Tharp, Scott and Hsiao, Wen-Yu and Shi, Qiuying},
title = {Testing insulin‐like growth factor messenger RNA–binding protein 3 as a surrogate immunohistochemical marker for indeterminate thyroid nodules with THADA fusion in both cytologic and surgical specimens},
journal = {Cancer Cytopathology},
year = {2026},
doi = {10.1002/cncy.70076}
}
EUVIMED